![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
In Vitro Resistance Analysis of Merck's HCV NS5a Inhibitor MK-8742 Demonstrates Increased Potency AgainstClinical Resistance Variants and Improved Resistance Profile
|
|
|
Reported by Jules Levin
EASL 2012 April 18-22 Barcelona Spain
Rong Liu*, Rong (Stephanie) Kong, Paul Mann, Paul Ingravallo, Ying Zhai, Ellen Xia, Peter Meinke, David Olsen, Steve Ludmerer, Joseph Kozlowski, Craig Coburn. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
![EASL1.gif](../images/042312/042312-6/EASL1.gif)
![EASL2.gif](../images/042312/042312-6/EASL2.gif)
![EASL3.gif](../images/042312/042312-6/EASL3.gif)
![EASL4.gif](../images/042312/042312-6/EASL4.gif)
![EASL5.gif](../images/042312/042312-6/EASL5.gif)
![EASL6.gif](../images/042312/042312-6/EASL6.gif)
![EASL7.gif](../images/042312/042312-6/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|